Why Biotech Stocks Are Celebrating This Nail-Biter

Live updates

1. 3h ago

   UniQure to File FDA Application for Huntington's Therapy

   UniQure is preparing a licensing application for its AMT-130 gene therapy. This action follows a reversal by the FDA after a prior disagreement. Biotech stocks climbed on Wednesday following this news.

   What's confirmed:

   • UniQure plans to submit a licensing application to the FDA for its AMT-130 gene therapy targeting Huntington's disease.
   • The FDA reversed a previous position following a dispute.

   Still unconfirmed:

   • Biotech stocks rose Wednesday due to the UniQure development.
   • Biotech stocks gained over 75% after hitting a low in April due to acquisitions and clinical data.
   • The biotech sector continues to trade at a discount.
   confidence 90%
2. 3d ago

   UniQure Stock Surges Following FDA Shift on Huntington's Gene Therapy

   UniQure plans to submit a licensing application to the FDA for its AMT-130 gene therapy targeting Huntington's disease. The move follows a reversal by the agency after a previous dispute. Biotech stocks rose Wednesday as a result of this development.

   What's confirmed:

   • UniQure intends to seek FDA approval for its Huntington's disease gene therapy.
   • The FDA reversed its previous position regarding the gene therapy treatment.
   • UniQure shares experienced a significant price increase following the news.
   • The treatment in question is identified as AMT-130.

   Still unconfirmed:

   • UniQure stock surged 81%.
   • UniQure stock soared 78%.
   • The FDA is giving CRL recipients another chance following the exit of Makary.
   confidence 90%